Emil T. Kuriakose

Dr. Kuriakose was promoted to Chief Medical Officer from Vice President and Head of Clinical Development in November 2021. Prior to joining Calithera in 2017, Dr. Kuriakose was at Novartis Oncology where he led the US Clinical Development and Medical Affairs Group for Farydak (panobinostat), supporting the NDA filing and launch in multiple myeloma. He subsequently led early phase development of several drugs in solid and hematologic malignancies as Global Clinical Program Lead at the Novartis Institute for Biomedical Research (NIBR). Dr. Kuriakose completed his clinical training in hematology/oncology at Weill Cornell Medical College, including a research fellowship in myeloproliferative neoplasms at Memorial Sloan Kettering Cancer Center. He completed his residency training in internal medicine at UT Southwestern Medical Center in Dallas, TX. Dr. Kuriakose received his MD from Stony Brook University School of Medicine and his Bachelor of Science in neuroscience from New York University.